Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial - The Lancet Respiratory Medicine
Medicines Update sur Twitter : "Are you aware that NACSYS® (acetylcysteine) is the preferred oral mucolytic in NHSGGC and should be considered 1st line for COPD patients unless otherwise directed by a